Collected clinical data for CL (l/h) and Vss (l/kg) after intravenous administration for 17 different compounds
| Compound | CL | Vss | ||||||
|---|---|---|---|---|---|---|---|---|
| No. of Trials | Total No. of Subjects | Mean CL (range)a | Mean %CV (range) | No. of Trials | Total No. of Subjects | Mean Vss (range)a | Mean %CV (range) | |
| Talinolol | 7 | 72 | 22.8 (19.1–29.1) | 16 (11–26) | NA | NA | NA | NA |
| Propranolol | 12 | 102 | 52 (30–76) | 17 (3–41) | NA | NA | NA | NA |
| Cisatracurium | 12 | 210 | 20.5 (15.4–25.8) | 18 (3–32) | NA | NA | NA | NA |
| Acetaminophen | 11 | 146 | 19.4 (15.9–22.3) | 19 (7–31) | 12 | 146 | 0.99 (0.84–1.14) | 19 (11–27) |
| Lidocaine | 11 | 104 | 54 (31.5–77.7) | 20 (6–32) | 9 | 90 | 2.28 (1.47–3.34) | 21 (9–28) |
| Propofol | 15 | 305 | 127 (78–228) | 21 (5–60) | NA | NA | NA | NA |
| Metronidazole | 17 | 182 | 4.30 (2.10–6.43) | 21 (6–43) | 12 | 184 | 0.67 (0.51–0.80) | 24 (7–50) |
| Theophylline | 21 | 230 | 3.5 (2.1–4.7) | 22 (6–83) | NA | NA | NA | NA |
| Ciprofloxacin | 18 | 265 | 32.1 (18.3–52.2) | 23 (10–60) | 15 | 190 | 2.25 (1.82–2.91) | 21 (13–39) |
| Midazolam | 33 | 570 | 28.6 (13.9–67.6) | 23 (6–46) | 21 | 251 | 1.30 (0.67–2.97) | 17 (2–40) |
| Antipyrine | 10 | 257 | 2.76 (1.85–3.91) | 23 (6–48) | 10 | 297 | 0.59 (0.48–0.72) | 14 (4–33) |
| Digoxin | 18 | 202 | 12.8 (4.5–24.5) | 25 (13–47) | 8 | 110 | 6.39 (3.45–8.41) | 32 (11–64) |
| Furosemide | 15 | 99 | 9.3 (6.2–16.1) | 25 (7–50) | 11 | 72 | 0.15 (0.11–0.21) | 22 (6–58) |
| Thiopental | 18 | 180 | 13.2 (9.2–16.8) | 29 (11–56) | 12 | 117 | 2.05 (1.19–2.88) | 37 (14–73) |
| Lorazepam | 21 | 196 | 4.55 (2.52–8.32) | 30 (10–49) | 15 | 136 | 1.45 (1.25–1.85) | 18 (8–34) |
| Diazepam | 21 | 301 | 1.64 (1.01–2.69) | 31 (11–51) | 14 | 152 | 1.17 (0.82–1.83) | 32 (11–57) |
| Alfentanil | 14 | 193 | 18.5 (6.6–39.1) | 40 (7–68) | NA | NA | NA | NA |
NA, not applicable (data were not available).
↵a Arithmetic mean of clearance.